<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38166755</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Effects of antivirals on patients with COVID-19 breakthrough.</ArticleTitle><Pagination><StartPage>25</StartPage><MedlinePgn>25</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-023-08952-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antivirals have been given widely for patients with COVID-19 breakthrough in Asian countries, creating a "black market" for unapproved and unprescribed medications. More evidence is needed to clarify the benefits of antivirals in these settings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a random-sampling retrospective cohort study at a general hospital in Vietnam. We recruited patients with mild-to-moderate COVID-19 breakthrough who were given either standard of care (SoC) alone or SoC&#x2009;+&#x2009;antiviral. Primary outcome was residual respiratory symptoms that lasted&#x2009;&gt;&#x2009;7 days. Secondary outcome was long COVID-19, diagnosed by specialized physicians. We used logistic regression to measure odds ratio (OR), in addition to a sensitivity and subgroup analyses to further explore the results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 142 patients (mean age 36.2&#x2009;&#xb1;&#x2009;9.8) were followed. We recorded residual symptoms in 27.9% and 20.3% of the SoC and SoC&#x2009;+&#x2009;antiviral group, while the figures for long COVID-19 were 11.8% and 8.1%, respectively. Antiviral use was not significantly associated with lower the risks of residual symptoms (OR&#x2009;=&#x2009;0.51, 95% CI: 0.22-1.20, p&#x2009;=&#x2009;0.12) or long COVID-19 (OR&#x2009;=&#x2009;0.55, 95% CI: 0.16-1.90, p&#x2009;=&#x2009;0.35). The sensitivity and subgroup analyses did not show any significant differences between the study groups (all p&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Antivirals were not associated with faster resolution of respiratory symptoms or lower risks of long COVID-19. Further studies should focus on different antivirals to confirm their effects on different sub-populations. Meanwhile, antivirals should only be used in very high-risk patients to avoid excessive costs and harms.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Hong Tham</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Nguyen Tat Thanh University, 72820, HCMC, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai-Phan</LastName><ForeName>Tuong-Anh</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Surgical Gastroenterology, Nhan Dan Gia Dinh Hospital, 72316, HCMC, Vietnam.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Planning, Nhan Dan Gia Dinh Hospital, 72316, HCMC, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truong-Nguyen</LastName><ForeName>Kim-Huong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Nhan Dan Gia Dinh Hospital, 72316, HCMC, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Minh-Hoang</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>NTT Hi-Tech Institute, Nguyen Tat Thanh University, 72820, HCMC, Vietnam. tmhoang@ntt.edu.vn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000718127">COVID-19 breakthrough infections</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral agents</Keyword><Keyword MajorTopicYN="N">Breakthrough Infections</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Vietnam</Keyword></KeywordList><CoiStatement>All authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38166755</ArticleId><ArticleId IdType="pmc">PMC10763260</ArticleId><ArticleId IdType="doi">10.1186/s12879-023-08952-z</ArticleId><ArticleId IdType="pii">10.1186/s12879-023-08952-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19&#x2013;11 March 2020. Accessed August 02., 2022. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</Citation></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Accessed January 05., 2023. Available from: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Butt AA, Guerrero MD, Canlas EB, et al. Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar. Nat Commun. 2023;14(1):24. doi: 10.1038/s41467-022-35653-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35653-z</ArticleId><ArticleId IdType="pmc">PMC9808756</ArticleId><ArticleId IdType="pubmed">36596793</ArticleId></ArticleIdList></Reference><Reference><Citation>Homan T, Mazzilli S, Chieti A, et al. Covid-19 vaccination programme effectiveness against SARS-CoV-2 related Infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study. Sci Rep. 2022;12(1):18597. doi: 10.1038/s41598-022-23235-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23235-4</ArticleId><ArticleId IdType="pmc">PMC9632568</ArticleId><ArticleId IdType="pubmed">36329239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan PD, Charlett A, Birrell P, et al. Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study. Nat Commun. 2022;13(1):4834. doi: 10.1038/s41467-022-32458-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32458-y</ArticleId><ArticleId IdType="pmc">PMC9382625</ArticleId><ArticleId IdType="pubmed">35977938</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293&#x2013;302. doi: 10.1016/s1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID-19 after Vaccination: Possible Breakthrough Infection. Updated June 23., 2022. Accessed November 20, 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html.</Citation></Reference><Reference><Citation>Goga A, Bekker LG, Garrett N, et al. Breakthrough SARS-CoV-2 Infections during periods of delta and omicron predominance, South Africa. Lancet. 2022;400(10348):269&#x2013;71. doi: 10.1016/s0140-6736(22)01190-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)01190-4</ArticleId><ArticleId IdType="pmc">PMC9259009</ArticleId><ArticleId IdType="pubmed">35809579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough Infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57&#x2013;65. doi: 10.1038/s41577-021-00662-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00662-4</ArticleId><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon KT. Immune responses and breakthrough Infections after COVID-19 vaccination. J Korean Med Sci. 2023;38(20):e185. doi: 10.3346/jkms.2023.38.e185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e185</ArticleId><ArticleId IdType="pmc">PMC10202613</ArticleId><ArticleId IdType="pubmed">37218356</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Therapeutics and COVID-19: Living guideline (published 3 March 2022). Accessed 27 April 2022. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4.</Citation><ArticleIdList><ArticleId IdType="pubmed">35917393</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Morgan R, Shumaker A et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (Version 10.0.0). Accessed 20 September 2022. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494372</ArticleId><ArticleId IdType="pubmed">36063397</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed 20 September 2022. Available from: https://www.covid19treatmentguidelines.nih.gov/.</Citation></Reference><Reference><Citation>Vietnam Ministry of Health. Guideline for diagnosis and treatment of COVID-19 (Decision 3416/Q&#x110;&#x2013;BYT, issued July 14., 2021). Accessed 15 July 2021. Available from: https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quyet-dinh-3416-QD-BYT-2021-Huong-dan-chan-doan-COVID-19-do-chung-vi-rut-Corona-moi-481044.aspx.</Citation></Reference><Reference><Citation>World Health Organization. COVID-19 Clinical management: living guidance (published Jan 25, 2021). Accessed 27 July 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.</Citation></Reference><Reference><Citation>Harris PA, Swafford J, Serdoz ES, et al. MyCap: a flexible and configurable platform for mobilizing the participant voice. JAMIA Open. 2022;5(2):ooac047. doi: 10.1093/jamiaopen/ooac047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooac047</ArticleId><ArticleId IdType="pmc">PMC9165428</ArticleId><ArticleId IdType="pubmed">35673353</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services. What is Long COVID? Accessed January 16., 2023. Available from: https://www.covid.gov/longcovid/definitions.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19): Post COVID-19 condition. Accessed January 16., 2023. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Accessed January 2., 2021. Available from: https://www.nice.org.uk/guidance/ng188.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Power and Sample Size. Calculate Sample Size Needed to Compare 2 Proportions: 2-Sample, 2-Sided Equality. Accessed 15. July 2022. Available from: http://powerandsamplesize.com/Calculators/Compare-2-Proportions/2-Sample-Equality.</Citation></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough Infections in Vaccinated Health Care workers. N Engl J Med. 2021;385(16):1474&#x2013;84. doi: 10.1056/NEJMoa2109072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109072</ArticleId><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Available from: https://apps.who.int/iris/handle/10665/206936.</Citation></Reference><Reference><Citation>Gopinath S, Ishak A, Dhawan N, et al. Characteristics of COVID-19 breakthrough Infections among vaccinated individuals and Associated Risk factors: a systematic review. Trop Med Infect Dis. 2022;7(5):81. doi: 10.3390/tropicalmed7050081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed7050081</ArticleId><ArticleId IdType="pmc">PMC9144541</ArticleId><ArticleId IdType="pubmed">35622708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P, Gebo K. COVID-19: management of adults with acute Illness in the outpatient setting. In: Elmore JG, editor. UpToDate. UpToDate; 2023.</Citation></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114(12):865&#x2013;71. doi: 10.1093/qjmed/hcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 Infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022;13(1):6152. doi: 10.1038/s41467-022-33825-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of Treatment with Nirmatrelvir and the risk of Post-COVID-19 Condition. JAMA Intern Med. 2023;e230743. 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022;28(4):602&#x2013;8. doi: 10.1016/j.cmi.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8747778</ArticleId><ArticleId IdType="pubmed">35026375</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon JH, Lau JSY, Coldham A, et al. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine. 2022;54:101703. doi: 10.1016/j.eclinm.2022.101703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101703</ArticleId><ArticleId IdType="pmc">PMC9583769</ArticleId><ArticleId IdType="pubmed">36284645</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zl&#xfc;&#x15f;en B, Kozan &#x15e;, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40(12):2575&#x2013;83. doi: 10.1007/s10096-021-04307-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-021-04307-1</ArticleId><ArticleId IdType="pmc">PMC8335450</ArticleId><ArticleId IdType="pubmed">34347191</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>